Trial Profile
A Phase 1 Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Jul 2019
Price :
$35
*
At a glance
- Drugs KHK 6640 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 06 Dec 2016 Status changed from recruiting to completed.
- 09 Mar 2015 New trial record